Aktieanalys

Bactiguard: Q2, COVID-19 hampering performance - SEB

SEB Publicerad: 15 Jul 2021 09:27

Bactiguard’s Q2 sales of SEK 46m were in line with our expectations, however, excluding a milestone payment from Zimmer Biomet (SEK 8.5m) that we have included for H2/21, sales were weaker than we had expected. Q2 adj. EBITDA amounted to SEK 2m. Bactiguard comments that it saw a continued stabilisation of licence revenues from BD and it expects the roll-out of vaccines to gradually have a positive effect on the return to a normal situation for healthcare.

https://research.sebgroup.com/corporate/reports/109398

Nyheter om Bactiguard

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!